Drug Profile


Alternative Names: FE 200 440

Latest Information Update: 17 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Oligopeptides; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility
  • No development reported Preterm labour

Most Recent Events

  • 17 Aug 2015 Phase-II development is ongoing for Female infertility (implantation support) in Europe, Australia and Canada
  • 17 Aug 2015 No recent reports on development identified - Phase-II for Preterm labour in Belgium, Czech Republic, Romania, Poland, Lithuania, Finland (IV)
  • 01 May 2015 Ferring completes a phase II trial in Female infertility in Australia, Belgium, Canada, Czech Republic, Poland, Spain (NCT01723982)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top